Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients

Clinical Cancer Research

Volumn 10, Issue 22, 2004, Pages 7457-7465

  Friedrich, Martin G ^a,c   Weisenberger, Daniel J ^a   Cheng, Jonathan C ^a   Chandrasoma, Shahin ^a   Siegmund, Kimberly D ^a   Gonzalgo, Mark L ^d   Toma, Marieta I ^c   Huland, Hartwig ^c   Yoo, Christine ^a   Tsai, Yvonne C ^a   Nichols, Peter W ^b   Bochner, Bernard H ^e   Jones, Peter A ^a   Liang, Gangning ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; COLLAGEN TYPE 2; DEATH ASSOCIATED PROTEIN KINASE; DEATH RECEPTOR 3; DEATH RECEPTOR 5; DNA; ENDOTHELIN B RECEPTOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; LIPOPOLYSACCHARIDE INDUCED TUMOR NECROSIS FACTOR ALPHA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P14; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TELOMERASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DIAGNOSTIC VALUE; DNA METHYLATION; GENE SILENCING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; NON INVASIVE MEASUREMENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; URINE SEDIMENT;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DNA PRIMERS; HUMANS; LIPOPOLYSACCHARIDES; MIDDLE AGED; MUCOUS MEMBRANE; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 9344235475     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0930     Document Type: Article

References (39)

1. Holmang S, Hedelin H, Anderstrom C, et al. Recurrence and progression in low grade papillary urothelial tumors. J Urol 1999;162:702-7.
2. Chopin DK, Gattegno B. Superficial bladder tumors. Eur Urol 2002;42:533-41.
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
4. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
5. Liang G, Salem CE, Yu MC, et al. DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics 1998;53:260-8.
6. Salem CE, Markl ID, Bender CM, et al. PAX6 methylation and ectopic expression in human tumor cells. Int J Cancer 2000;87:179-85.
7. Salem C, Liang G, Tsai YC, et al. Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res 2000;60:2473-6.
8. Liang G, Robertson KD, Talmadge C, Sumegi J, Jones PA. The gene for a novel transmembrane protein containing epidermal growth factor and follistatin domains is frequently hypermethylated in human tumor cells. Cancer Res 2000;60:4907-12.
9. Tada Y, Wada M, Taguchi K, et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002;62:4048-53.
10. Jones PA. The DNA methylation paradox. Trends Genet 1999;15:34-7.
11. Jones PA. Cancer. Death and methylation. Nature (Lond) 2001;409:141, 143-4.
12. Chan MW, Chan LW, Tang NL, et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003;104:611-6.
13. Ribeiro-Filho LA, Franks J, Sasaki M, et al. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinog 2002;34:187-98.
14. Horikawa Y, Sugano K, Shigyo M, et al. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ. J Urol 2003;169:1541-5.
15. Bornman DM, Mathew S, Alsruhe J, Herman JG, Gabrielson E. Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am J Pathol 2001;159:831-5.
16. Conway KE, McConnell BB, Bowring CE, et al. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 2000;60:6236-42.
17. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (Lond) 2001;409:207-11.
18. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
19. Babidge WJ, Butler LM, Burton MA, Cowled PA. Methylation of CpG sites in exon 2 of the bcl-2 gene occurs in colorectal carcinoma. Anticancer Res 2001;21:2809-14.
20. Pao MM, Tsutsumi M, Liang G, et al. The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet 2001;10:903-10.
21. Ekert PG, Silke J, Vaux DL. Caspase inhibitors. Cell Death Differ 1999;6:1081-6.
22. Ehrlich M, Jiang G, Fiala E, et al. Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene 2002;21:6694-702.
23. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-60.
24. Myokai F, Takashiba S, Lebo R, Amar S. A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor alpha gene expression: molecular cloning, sequencing, characterization, and chromosomal assignment. Proc Natl Acad Sci USA 1999;96:4518-23.
25. 2+ mobilization promotes cytochrome c release during apoptosis. J Biol Chem 2002;277:20301-8.
26. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
27. Markl ID, Jones PA. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res 1998;58:5348-53.
28. Sobin L, Wittekind C. TNM classification of malignant tumors, 5th ed. New York: John Wiley & Sons; 1997.
29. Widschwendter M, Siegmund KD, Muller HM, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004;64:3807-13.
30. Perrone F, Oggionni M, Birindelli S, et al. TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. Int J Cancer 2003;105:196-203.
31. Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002;8:464-70.
32. Guilleret I, Yan P, Guillou L, et al. The human telomerase RNA gene (hTERC) is regulated during carcinogenesis but is not dependent on DNA methylation. Carcinogenesis (Lond) 2002;23:2025-30.
33. Zangemeister-Wittke U, Leech SH, Olie RA, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000;6:2547-55.
34. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279-84.
35. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66.
36. Mao L, Schoenberg MP, Scicchitano M, et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science (Wash DC) 1996;271:659-62.
37. Friedrich MG, Erbersdobler A, Schwaibold H, et al. Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer. J Urol 2000;163:1039-42.
38. Battagli C, Uzzo RG, Dulaimi E, et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 2003;63:8695-9.
39. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004;10:1887-93.